Inside the research
Globus Medical, Inc.
GMED Research profile · latest available data
Price overview
$74.52
▲ +0.25 (+0.3%)
| 52w hi | $96.82 |
|---|---|
| 52w lo | $55.10 |
| Vol | 1.56M |
| As of | 25 Sep 2026 |
The Verdict
Our score -0.22
| Short | -0.39 |
|---|---|
| Medium | -0.16 |
| Long | -0.03 |
computed 2026-09-27
Key fundamentals
Globus Medical, Inc.
Healthcare · Medical Devices
| Market cap | $10.01B |
|---|---|
| Enterprise value | $9.52B |
| Trailing P/E | 19.06x |
| Forward P/E | 13.80x |
| EV / EBITDA | 9.43x |
| P / S (ttm) | 3.18x |
| Profit margin | 17.0% |
| Return on equity | 11.8% |
| Revenue growth | +5.9% |
| Earnings growth | -26.2% |
| Debt / equity | 2.35 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.18 | |
| Sector | +0.08 | |
| Technical | -0.31 | |
| Earnings | +0.00 | |
| Sentiment | +0.05 |
macro × 1.00 · 2026-09-27
Business overview
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems. In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Risk Metrics
| Beta vs SPX | 0.95 |
|---|---|
| Corr SPX | 0.35 |
| Annual vol | 44.2% |
| Annual ret | +12.0% |
| Sharpe | 0.27 |
| Max DD | -44.4% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $111.50 |
|---|---|
| High / Low | $123.00 / $92.00 |
| Median | $115.00 |
| Analysts | 12 |
| Strong Buy | 4 | |
|---|---|---|
| Buy | 6 | |
| Hold | 4 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-05-08 | Wells Fargo | → Overweight |
| 2026-05-08 | RBC Capital | → Outperform |
| 2026-05-08 | Needham | → Buy |
| 2026-02-26 | Wells Fargo | → Overweight |
| 2026-02-25 | Needham | → Buy |
| 2026-02-25 | Barclays | → Overweight |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-06 | Earnings Release, Exhibits | read |
| 2026-06-04 | Officer / Director Change, Shareholder Vote… | read |
| 2026-05-07 | Earnings Release, Exhibits | read |
| 2026-03-23 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-02-24 | Earnings Release, Exhibits | read |
| 2026-01-07 | Earnings Release, Exhibits | read |
| 2025-11-06 | Earnings Release, Exhibits | read |
| 2025-08-07 | Earnings Release, Exhibits | read |
| 2025-07-21 | Earnings Release, Officer / Director Change… | read |
| 2025-06-05 | Officer / Director Change, Shareholder Vote… | read |
| 2025-05-15 | Other Material Event, Exhibits | read |
| 2025-05-08 | Earnings Release, Exhibits | read |
SEC Filings
The Long Run
FY 2012–2025 · 14 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $1.57B | +25.6% | |
| Gross profit | $759.12M | +23.3% | |
| Operating income | $479.82M | +11.6% | |
| Net income | $537.87M | +33.0% | |
| Cash from ops | $243.50M | +9.3% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $74.53 | $75.10 | $73.69 | $74.52 | 1.56M |
| Sep 24 | $74.21 | $74.99 | $73.70 | $74.27 | 1.63M |
| Sep 23 | $74.95 | $75.34 | $73.75 | $73.96 | 1.46M |
| Sep 22 | $74.99 | $75.73 | $74.37 | $75.19 | 1.93M |
| Sep 21 | $74.00 | $74.41 | $73.17 | $74.29 | 1.25M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →